Mankyu Park
Direttore/Membro del Consiglio presso Coagulant Therapeutics, Inc.
Posizioni attive di Mankyu Park
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Mankyu Park
Precedenti posizioni note di Mankyu Park
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| DTCP Management GmbH | Corporate Officer/Principal | - | - |
Formazione di Mankyu Park
| Goizueta Business School-Emory | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Corea del Sud | 2 |
Posizioni
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Settori
| Consumer Services | 2 |
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
| DTCP Management GmbH | Finance |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Health Technology |
- Borsa valori
- Insiders
- Mankyu Park
- Esperienza
